The Institute of Cancer Research (ICR) posted on LinkedIn:
“We’re thrilled to announce an exciting new collaboration.
Scientists in our Centre for Immunotherapy of Cancer are working with life sciences company QBiotics Group Limited on the development of a potential new cancer drug.
Together we are investigating its effects in samples from patients with head and neck cancer taking part in a clinical trial. Fascinatingly, the potential drug – called tignanol tiglate was isolated from the seed of the North Australian blushwood tree.
The seeds piqued the interest of QBiotics’ scientists after they noticed that the musky-rat kangaroo, the world’s smallest kangaroo found the seeds of its fruit unpalatable.
Read more about our collaboration here.”